<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397761</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000513169</org_study_id>
    <secondary_id>WHC-MRI-GU-2006-097</secondary_id>
    <nct_id>NCT00397761</nct_id>
  </id_info>
  <brief_title>Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer</brief_title>
  <official_title>Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine and paclitaxel (albumin-stablized&#xD;
      nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving more than one drug (combination&#xD;
      chemotherapy) before surgery may make the tumor smaller and reduce the amount of normal&#xD;
      tissue that needs to be removed.&#xD;
&#xD;
      PURPOSE: This phase II/III trial is studying how well giving capecitabine together with&#xD;
      paclitaxel (albumin-stabilized nanoparticle formulation) works in treating women undergoing&#xD;
      surgery for stage II or stage III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the rate of pathological complete response (i.e., tumor completely gone) in&#xD;
           women with previously untreated, unresected, stage II-IIIB breast cancer treated with&#xD;
           neoadjuvant therapy comprising capecitabine and paclitaxel (albumin-stabilized&#xD;
           nanoparticle formulation) (Abraxane^速).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the safety of this regimen in these patients.&#xD;
&#xD;
        -  Determine overall clinical response rate in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive up to 4 courses of capecitabine and paclitaxel (nanoparticle&#xD;
      albumin-stabilized formulation) (Abraxane^速) in the absence of disease progression. Patients&#xD;
      then undergo definitive surgical resection of the tumor off study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2006</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall clinical response rate</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed infiltrating carcinoma of the breast or inflammatory breast&#xD;
             cancer&#xD;
&#xD;
               -  Stage II-IIIB disease (T1-4, N1-2, M0)&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  Previously unresected disease&#xD;
&#xD;
          -  High-risk disease that is not resectable by lumpectomy alone&#xD;
&#xD;
          -  Any HER2/neu status (positive, negative, or unknown) allowed&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Any estrogen/progesterone status (positive, negative, or unknown) allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm続&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm続&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST &lt; 2.5 times ULN (5 times ULN if due to Gilbert's disease)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 times ULN (5 times ULN if due to Gilbert's disease)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Aggarwal, DO, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Cancer Institute at Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 8, 2006</study_first_submitted>
  <study_first_submitted_qc>November 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2006</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <keyword>inflammatory breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

